Illumina's Illuminating Results

The problem with a company's stock going up 45% since the beginning of the year is that its employees tend to cash in their stock options. Illumina (Nasdaq: ILMN  ) faced that problem in the third quarter as its bottom line was eroded by $8.7 million in non-cash stock compensation.

The company experienced a stellar 82% year-over-year increase in revenue, but gross margins excluding non-cash charges slipped a whopping 700 basis points from the year-ago quarter to 63.1%, cutting into the bottom-line growth.

The change in gross margin was mostly due to the 206% year-over-year growth in sales of lower-margin instruments, including the new Genome Analyzer. Half of the 100 Analyzers that Illumina has so far sold were sold outside genome centers, and that bodes well for continued growth of instrument sales since there aren't that many large genome centers in the world. The placement of all those extra machines should drive sales of higher-margin consumable products used by the machines in the years to come.

Meanwhile, in the chip-making equivalent of "keeping up with the Joneses," Illumina is losing the battle of house size, but has a nice pool out back. The company's Human1M DNA Analysis BeadChip - which it began shipping at the end of last quarter -- contains considerably fewer markers than Affymetrix's (Nasdaq: AFFX  ) SNP Array 6.0 chip, but it gives the scientists information about duplications in the sample. This angle -- developed in collaboration with deCODE genetics (Nasdaq: DCGN  ) -- may not be as robust on Affymetrix's chip.

Illumina doesn't break down sales numbers for individual products, but it did mention that the Human1M DNA Analysis BeadChip is "rapidly become one of [its] best selling arrays ..."

Management remained fairly tight-lipped about its collaboration with 23andMe, which received a major investment from Google (Nasdaq: GOOG  ) last spring, but said that they would be able to talk about it more once 23andMe's product launches this quarter.

Illumina doesn't expect this quarter to be a fluke. The company guided for about 5% sequential increase for fourth-quarter revenues, even in the face of holiday slowdowns in laboratories. Illumina needs to sustain that growth into 2008 if it wants to maintain the lofty valuation that investors have bestowed upon it.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 539095, ~/Articles/ArticleHandler.aspx, 11/26/2014 12:44:37 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement